SCHEMBL5871999

SCHEMBL5871999

C=C(C(=O)OCCC)C(=O)OCCC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.48
THRB P10828 1/20 0.45
HCAR2 Q8TDS4 1/20 0.41
ALDH1A1 P00352 7/20 0.40
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.38
ESR1 P03372 1/20 0.38
CHRM1 P11229 1/20 0.38
SLC6A2 P23975 1/20 0.38
KDR P35968 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 1/20 0.37
RAD52 P43351 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ATM Q13315 1/20 0.34
NAAA Q02083 1/20 0.33
DGKA P23743 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15536700 0.93 ALDH1A1 (0.47) TSHRTHRBHCAR2ALDH1A1GAA
SCHEMBL6657193 0.91 TSHR (0.42) TSHRTHRBHCAR2ALDH1A1GAA
SCHEMBL629109 0.88 TSHR (0.44) TSHRTHRBHCAR2ALDH1A1GAA
SCHEMBL5408195 0.88 TSHR (0.48) TSHRTHRBHCAR2ALDH1A1GAA
SCHEMBL21802370 0.87 TSHR (0.69) TSHRHCAR2ALDH1A1LMNARAD52
SCHEMBL18499281 0.85 TSHR (0.56) TSHRTHRBALDH1A1MAPTRAD52
SCHEMBL5871854 0.85 TSHR (0.61) TSHRTHRBHCAR2ALDH1A1SMN1; SMN2
SCHEMBL5871624 0.83 TSHR (0.70) TSHRHCAR2ALDH1A1LMNAHPGD
SCHEMBL138475 0.83 HCAR2 (0.48) TSHRTHRBHCAR2ALDH1A1GAA
SCHEMBL45789 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119552307-A Preparation method of ester modified SBC carbon five petroleum resin 恒河材料科技股份有限公司 2025-03-04 CN claimed
EP-3865520-B1 CURING AGENT COMPOSITION FOR CURING 2-METHYLENE-1,3-DICARBONYL COMPOUND NAMICS CORP (JP) 2024-02-28 EP disclosed
CN-113249041-B Resin composition 纳美仕有限公司 2023-08-15 CN disclosed
EP-3626751-B1 RESIN COMPOSITION NAMICS CORP (JP) 2023-05-17 EP disclosed
US-11634615-B2 Resin composition NAMICS CORPORATION (JP) 2023-04-25 US disclosed
CN-112789299-B Curing agent composition for curing 2-methylene-1, 3-dicarbonyl compounds 纳美仕有限公司 2023-02-21 CN disclosed
CN-114341215-A Curable composition 株式会社日本触媒 2022-04-12 CN disclosed
US-20220089504-A1 Curing Agent, Method for Producing Cement Structure with Coating Film, Shrinkage Reduction Method and Drying Suppression Method for Cement Molded Body, and Method for Suppressing Penetration of Deterioration Factor into Cement Structure NIPPON SHOKUBAI CO., LTD. (JP) 2022-03-24 US disclosed
CN-111278869-B Resin composition 纳美仕有限公司 2022-02-11 CN disclosed
US-11230617-B2 Resin composition NAMICS CORPORATION (JP) 2022-01-25 US disclosed
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1123915-B1 Process for producing alpha, beta-unsaturated carboxylic acid esters and catalyst for use in such process NIPPON CATALYTIC CHEM IND (JP) 2004-07-28 EP disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed
US-6541656-B2 Reacting an alpha, beta unsaturated carboxylic acid ester with a heterocyclic oxygen nitrogen, or sulfur compound NIPPON SHOKUBAI COMPANY, LTD. (JP) 2003-04-01 US disclosed
US-20010034300-A1 Reacting an alpha, beta unsaturated carboxylic acid ester with a heterocyclic oxygen nitrogen, or sulfur compound NIPPON SHOKUBAI COMPANY LTD. (JP) 2001-10-25 US disclosed
EP-1123915-A1 Process for producing alpha, beta-unsaturated carboxylic acid esters and catalyst for use in such process Nippon Shokubai Co., Ltd. (JP) 2001-08-16 EP disclosed
EP-0102404-A1 Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof STERLING DRUG INC. (US) 1984-03-14 EP disclosed
US-4349558-A Anti-inflammatory 8H-phenanthro-[2,3-c]pyrazole derivatives STERLING DRUG INC. (US) 1982-09-14 US disclosed
US-4056543-A FROM A SUBSTITUTED NORBORNENE AND A HALOFORMATE, ALKYLLITHIUM AMIDE CATALYST EASTMAN KODAK COMPANY (US) 1977-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089504-A1 Curing Agent, Method for Producing Cement Structure with Coating Film, Shrinkage Reduction Method and Drying Suppression Method for Cement Molded Body, and Method for Suppressing Penetration of Deterioration Factor into Cement Structure WDR1, WDR82, CECR2 TSHR 3849/4885THRB 2568/4885HCAR2 519/4885
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 TSHR 2365/4885THRB 3266/4885HCAR2 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.